Tabata, T.; Petitt, M.; Li, J.; Chi, X.; Chen, W.; Yurgelonis, I.; Wellnitz, S.; Bredl, S.; Vicente, T.; Yang, X.;
et al. Neutralizing Antibodies to Human Cytomegalovirus Recombinant Proteins Reduce Infection in an Ex Vivo Model of Developing Human Placentas. Vaccines 2022, 10, 1074.
https://doi.org/10.3390/vaccines10071074
AMA Style
Tabata T, Petitt M, Li J, Chi X, Chen W, Yurgelonis I, Wellnitz S, Bredl S, Vicente T, Yang X,
et al. Neutralizing Antibodies to Human Cytomegalovirus Recombinant Proteins Reduce Infection in an Ex Vivo Model of Developing Human Placentas. Vaccines. 2022; 10(7):1074.
https://doi.org/10.3390/vaccines10071074
Chicago/Turabian Style
Tabata, Takako, Matthew Petitt, Julia Li, Xiaoyuan Chi, Wei Chen, Irina Yurgelonis, Sabine Wellnitz, Simon Bredl, Tiago Vicente, Xinzhen Yang,
and et al. 2022. "Neutralizing Antibodies to Human Cytomegalovirus Recombinant Proteins Reduce Infection in an Ex Vivo Model of Developing Human Placentas" Vaccines 10, no. 7: 1074.
https://doi.org/10.3390/vaccines10071074
APA Style
Tabata, T., Petitt, M., Li, J., Chi, X., Chen, W., Yurgelonis, I., Wellnitz, S., Bredl, S., Vicente, T., Yang, X., Dormitzer, P. R., & Pereira, L.
(2022). Neutralizing Antibodies to Human Cytomegalovirus Recombinant Proteins Reduce Infection in an Ex Vivo Model of Developing Human Placentas. Vaccines, 10(7), 1074.
https://doi.org/10.3390/vaccines10071074
